R. Safaralizadeh

Targeting lncRNA PVT1/miR‐145‐5p/ABCC‐1 Pathway Enhances Paclitaxel Sensitivity and Suppresses Melanoma Progression

Background As a highly aggressive type of skin cancer, melanoma cells show significant resistance against a variety of chemotherapeutics, such as paclitaxel, which limits the efficacy of the treatment. Studies have highlighted the potential role of noncoding RNA dysregulation in melanoma, affecting tumor progression an...

Expression profiles of long non-coding RNAs ROCR, CFLAR-AS1, ST7-AS1, and ST7-AS2 in diffuse large B-cell lymphoma: a case-control study focusing on GCB and non-GCB subtypes

Diffuse Large B-cell lymphoma (DLBCL) is subdivided into the Germinal Center B-cell (GCB) and non-Germinal Center B-cell (non-GCB)/Activated B-cell (ABC) subtypes, with significant clinical, phenotypic, and genetic variability. Investigating DLBCL’s molecular mechanisms and developing tailored treatment strategie...

Expression of long non‑coding RNAs DIAPH3‑AS1, HMMR‑AS1, and SPATA3‑AS1 in patients with colorectal cancer: association with chemotherapy response and clinicopathological features

THE NOVEL LINCRNA JUNI FIND BY COMPUTATIONAL INVESTIGATION OF THE EXPRESSION PATTERNS OF LNCRNAS IN CORONARY ARTERY DISEASE

JUNI may represent a novel CAD-associated lncRNA and provide several of candidate lncRNAs for further investigation as potential biomarkers and regulatory molecules in CAD, although independent validation and mechanistic studies are required before clinical application.